• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Kontron finds a buyer

Article

U.K. ultrasound and patient monitoring firm Kontron Instruments found a buyer last month, only weeks after going into receivership. The company was purchased Feb. 5 by Innermail Ltd., a subsidiary of Charterhouse Group International, a private equity

U.K. ultrasound and patient monitoring firm Kontron Instruments found a buyer last month, only weeks after going into receivership. The company was purchased Feb. 5 by Innermail Ltd., a subsidiary of Charterhouse Group International, a private equity company based in New York City.

At the time it went into receivership, Kontron owed roughly $8 million to its creditors. Its assets were intellectual property rights to its monitoring products, an electronic assembly plant, raw materials, and stock, according to Kontron's receiver, KPMG, an international accounting firm also based in the U.K. (SCAN 2/17/99). Ninety Kontron employees lost jobs as a result of the company's failure, although KPMG anticipates that several of these employees will be hired by Innermail. Charterhouse Group was unavailable for comment on the Kontron purchase.

Related Videos
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.